

## ASX ANNOUNCEMENT MARKET RELEASE

27 November 2024

### ANNUAL GENERAL MEETING - LINK

Artrya Limited (ASX:AYA), ('Artrya' or the 'Company'), a medical technology company focused on commercialising its patented artificial intelligence platform that detects key coronary artery disease imaging markers, reminds shareholders that the Annual General Meeting of the Company (AGM) will be held on Thursday 28 November 2024 at 10:00am AWST.

The AGM will be held at Artrya's office, 1257 Hay Street, West Perth, Western Australia.

**AYA invites all shareholders to join the Company's Annual General Meeting WEBCAST commencing at 10:00am AWST (1:00pm EDST) on Thursday 28 November 2024 by clicking on the following link:**

[https://us02web.zoom.us/webinar/register/WN\\_I\\_7eQEqQTiCh-v0VGqOYOg](https://us02web.zoom.us/webinar/register/WN_I_7eQEqQTiCh-v0VGqOYOg)

*This announcement was approved by the Board.*

**For further information please contact:**

**Investor Enquiries:**

Danny Younis  
+61 420 293 042  
[danny.younis@automicgroup.com.au](mailto:danny.younis@automicgroup.com.au)

**Media Relations:**

Rama Razy  
+61 498 440 142  
[rama.razy@automicgroup.com.au](mailto:rama.razy@automicgroup.com.au)

**About Artrya**

Based in Perth, Australia, Artrya was founded in 2018 with operations starting in early 2019. The Company was listed on the Australian Securities Exchange (ASX: AYA) in 2021.

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of at-risk patients. The company has developed deep-learning algorithms pending regulatory submission for clearance and approval in the US that will serve to predict and prevent acute coronary events.

For more information, see [www.artrya.com](http://www.artrya.com)